• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Implants

Senseonics completes 365-day CGM study cohort

September 26, 2023 By Sean Whooley

Marketing image Senseonics Eversense E3 Ascensia Diabetes Care

Senseonics (NYSE:SENS) announced today that it completed its ENHANCE pivotal clinical study adult cohort for its 365-day Eversense CGM. Germantown, Maryland-based Senseonics’ ENHANCE study recorded the completed 365-day visit for the final study patient. The study evaluates the year-long implantable continuous glucose monitor in adults. It also has a pediatric cohort (ages 14 to 18), […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Featured, Implants, Patient Monitoring, Technology Tagged With: Senseonics

Elutia raises $26M for drug-eluting biomatrix tech

September 19, 2023 By Sean Whooley

Elutia Logo

Elutia (Nasdaq:ELUT) announced today that it entered into a securities purchase agreement worth total proceeds of $26.2 million. The drug-eluting biomatrix company expects the private placement financing to result in initial gross proceeds of approximately $10.5 million. The full exercise of warrants would add $15.8 million to reach a total of $26.2 million. Silver Spring, […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Implants, Regenerative Medicine, Stem Cells Tagged With: Elutia

Senseonics enters into $50M loan facility

September 11, 2023 By Sean Whooley

Senseonics logo

Senseonics (NYSE:SENS) announced today that it entered into a $50 million loan facility with Hercules Capital. The Germantown, Maryland-based long-term, implantable continuous glucose monitor (CGM) maker drew $25 million upon closing. Senseonics CFO Rick Sullivan said the facility provides increased financial flexibility for the company. It looks to continue collaborating with Ascensia Diabetes Car to […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Implants, Patient Monitoring, Technology Tagged With: Senseonics

GLP-1 startup i2o looks to revive diabetes drug-eluting implant from Intarcia

September 5, 2023 By Sean Whooley

Intarcia Therapeutics

i2o Therapeutics says it acquired the diabetes-treating assets of one-time medtech unicorn Intarcia Therapeutics. The Boston-based company acquired and integrated Intarcia’s proprietary assets and made a big personnel move. With CEO Ravi Srinivasan moving onto other opportunities, i2o named Kurt Graves as chair, president and CEO. Graves previously served as executive chair of the i2o […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Mergers & Acquisitions, Personnel, Regulatory/Compliance Tagged With: i2o Therapeutics, Intarcia Therapeutics, Personnel Moves

Glucotrack tabs former Medtronic veteran for a board director spot

August 31, 2023 By Sean Whooley

Erin Carter GlucoTrack board member LinkedIn headshot

Glucotrack (Nasdaq:GCTK) announced today that it appointed Erin Carter to its board of directors, naming her chair of its audit committee. Carter’s appointment comes just days after the implantable continuous glucose monitor (CGM) maker named Drinda Benjamin VP of marketing. She becomes a member of the board and chair of the audit committee, effective immediately. “We […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Implants, Patient Monitoring, Personnel, Technology Tagged With: Glucotrack, Personnel Moves

Implantable CGM maker Glucotrack names new VP of marketing

August 29, 2023 By Sean Whooley

Drinda Benjamin LinkedIn Glucotrack

Glucotrack (Nasdaq:GCTK) announced that it appointed Drinda Benjamin as its new vice president of marketing. Rutherford, New Jersey-based Glucotrack develops an implantable continuous glucose monitor (CGM). It designed its CGM for patients with type 1 and type 2 insulin-dependent diabetes. A recent feasibility study demonstrated reliable glucose measurements for two years post-implant for the device. […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Implants, Patient Monitoring, Personnel, Technology Tagged With: Glucotrack, Personnel, Personnel Moves

BioCorRx submits implantable opioid use disorder treatment to FDA for expanded access

August 15, 2023 By Sean Whooley

BioCorRx updated logo

BioCorRx announced today that it submitted to the FDA an expanded access program application for its BICX104 implantable naltrexone pellet. BICX104, a biodegradable implantable pellet, treats opioid use disorder (OUD). The expanded access program would enable the treatment to reach eligible patients before full FDA approval. The FDA program provides access to products before approval […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Pharmaceuticals, Regulatory/Compliance Tagged With: BioCorRx, FDA

This biodegradable brain implant delivers cancer-treating drugs

July 13, 2023 By Sean Whooley

Researchers say they developed a biodegradable brain implant capable of helping to deliver chemotherapy drugs directly to tumors. Medscape News reported that the research marks another step toward using ultrasound to combat cancer. According to the team, led by Thanh Nguyen, these drugs can penetrate the blood-brain barrier to reach these brain tumors. Nguyen serves […]

Filed Under: Drug-Device Combinations, Implants, Oncology, Research & Development, Technology Tagged With: University of Connecticut

Sernova reports positive interim data for Cell Pouch System

June 26, 2023 By Sean Whooley

Sernova Cell Pouch System Type 1 Diabetes

Sernova today announced positive interim data from the clinical trial of its Cell Pouch System in patients with type 1 diabetes. London, Ontario-based Sernova designed its proprietary Cell Pouch System as an implantable and scalable medical device. It forms a natural environment in the body for the long-term survival and function of therapeutic cells. Those […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Implants Tagged With: Sernova Inc

UnitedHealthcare to cover Senseonics Eversense E3 CGM

June 5, 2023 By Sean Whooley

Marketing image Senseonics Eversense E3 Ascensia Diabetes Care

Senseonics (NYSE:SENS) announced that UnitedHealthcare intends to begin providing coverage for its Eversense E3 CGM. Coverage of the continuous glucose monitor for people with type 1 and insulin-requiring type 2 diabetes goes into effect on July 1, 2023. UnitedHealthcare, the largest health insurance company in the U.S., covers more than 45 million lives. Its offerings […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Implants, Patient Monitoring, Technology Tagged With: Senseonics, UnitedHealthcare

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Interim pages omitted …
  • Page 23
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS